RxDoctor Payments Data

Mariam Nasiri, APRN

Acute Care · Hartford, CTNPI 1164916557

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 56.5% of the total. Among acute care clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,517in general payments, 2019–2025

Across 181 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$605
  • Genentech USA, Inc.$224
  • Bristol Myers Squibb$118
  • Lilly USA, LLC$91
  • Argenx US, Inc.$87
  • plus $405 from 11 others

What the payments were for

  • Food & beverage$3,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,517 in reported general payments places this provider in the 90th percentile of 239 acute care providers in Connecticut.

See all acute care providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,937
Medicare patients
107
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate38$47,090
QuliptaAtogepant28$30,825
UbrelvyUbrogepant15$21,157
Emgality PenGalcanezumab-Gnlm17$17,872
Ajovy SyringeFremanezumab-Vfrm16$11,793
Rivastigmine27$3,331
Pregabalin91$2,881
Gabapentin161$2,587
Propranolol Hcl ErPropranolol Hcl59$1,828
Carbamazepine ErCarbamazepine16$1,619
Memantine Hcl94$1,617
Donepezil Hcl144$1,105
Levetiracetam25$876
Nortriptyline Hcl35$598
Lidocaine13$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,989$51,98243 claims
PfizerNurtec Odt$605$47,09038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 239 acute care providers in Connecticut.

Other acute care in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →